Abstract
Background: Results of several studies suggest that serum amino acids monitoring in migraine might be useful as an objective measurement of the disease status.
Objective: The aim of the present work was to analyze the profile of aliphatic and aromatic amino acids in blood serum of migraine patients without and with aura between attacks.
Methods: A total number of 37 migraine patients (26 with migraine without aura and 11 with migraine with aura), mean age 39±12 years, and 40 age-matched healthy subjects as the control group, mean age 38±14 years, were included into the study. The levels of glutamic acid, glutamine, histidine (His), valine (Val), isoleucine, leucine (Leu), phenyloalanine, lysine were evaluated.
Results: The level of His was significantly higher in both groups of migraine patients (without and with aura) compared to the control group (F(2,74)=10.17, p=0.00). The levels of Val and Leu were significantly different in migraine without but not with aura, when compared with the control group (F(2,74)=4.70, p=0.01 and F(2,74)=4.39, p=0.02, respectively).
Conclusion: We found higher level of His in migraine patients without and with aura and lower level of Val and Leu in patients with migraine without aura.
Keywords: Amino acids, cortical spreading depression, migraine, neuronal pathogenesis.
CNS & Neurological Disorders - Drug Targets
Title:Changes in Serum Amino Acids in Migraine Patients without and with Aura and their Possible Usefulness in the Study of Migraine Pathogenesis
Volume: 14 Issue: 3
Author(s): Izabela Domitrz, Marek D. Koter, Malgorzata Cholojczyk, Wojciech Domitrz, Anna Baranczyk-Kuzma and Anna Kaminska
Affiliation:
Keywords: Amino acids, cortical spreading depression, migraine, neuronal pathogenesis.
Abstract: Background: Results of several studies suggest that serum amino acids monitoring in migraine might be useful as an objective measurement of the disease status.
Objective: The aim of the present work was to analyze the profile of aliphatic and aromatic amino acids in blood serum of migraine patients without and with aura between attacks.
Methods: A total number of 37 migraine patients (26 with migraine without aura and 11 with migraine with aura), mean age 39±12 years, and 40 age-matched healthy subjects as the control group, mean age 38±14 years, were included into the study. The levels of glutamic acid, glutamine, histidine (His), valine (Val), isoleucine, leucine (Leu), phenyloalanine, lysine were evaluated.
Results: The level of His was significantly higher in both groups of migraine patients (without and with aura) compared to the control group (F(2,74)=10.17, p=0.00). The levels of Val and Leu were significantly different in migraine without but not with aura, when compared with the control group (F(2,74)=4.70, p=0.01 and F(2,74)=4.39, p=0.02, respectively).
Conclusion: We found higher level of His in migraine patients without and with aura and lower level of Val and Leu in patients with migraine without aura.
Export Options
About this article
Cite this article as:
Domitrz Izabela, Koter D. Marek, Cholojczyk Malgorzata, Domitrz Wojciech, Baranczyk-Kuzma Anna and Kaminska Anna, Changes in Serum Amino Acids in Migraine Patients without and with Aura and their Possible Usefulness in the Study of Migraine Pathogenesis, CNS & Neurological Disorders - Drug Targets 2015; 14 (3) . https://dx.doi.org/10.2174/1871527314666150225144300
DOI https://dx.doi.org/10.2174/1871527314666150225144300 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Melanoma
Current Cancer Therapy Reviews Sodium Channel Blockers as Therapeutic Target for Treating Epilepsy: Recent Updates
Current Topics in Medicinal Chemistry Silencing the Brain May be Better than Stimulating it. The GABA Effect
Current Pharmaceutical Design Administration of Exogenous Surfactant and Cytosolic Phospholipase A2α Inhibitors may Help COVID-19 Infected Patients with Chronic Diseases
Coronaviruses Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients
Current Drug Targets Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Severe Asthma: Why do Some Children Not Respond to Treatment?
Current Pediatric Reviews CYP3A4-mediated Pharmacokinetic Interactions in Cancer Therapy
Current Drug Metabolism Childhood Infectious Encephalitis: An Overview of Clinical Features, Investigations, Treatment, and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology Editorial:Cannabis: Neurological Correlates in Abuse and Medical Use
CNS & Neurological Disorders - Drug Targets Is Exenatide Improving the Treatment of Type 2 Diabetes? Analysis of the Individual Clinical Trials with Exenatide
Reviews on Recent Clinical Trials Optic Nerve and Cerebral Edema in the Course of Diabetic Ketoacidosis
Current Neuropharmacology Medicinal Compound Celastrol As a Potential Clinical Anticancer Drug: Lessons Learned From Preclinical Studies
Clinical Cancer Drugs Pregabalin Dependence: A Case Report
Current Drug Safety Meal Replacement Beverage Twice a Day in Overweight and Obese Adults (MDRC2012-001)
Current Nutrition & Food Science Lymphatics and Inflammation
Current Medicinal Chemistry Ginkgo biloba Extract 761: A Review of Basic Studies and Potential Clinical Use in Psychiatric Disorders
CNS & Neurological Disorders - Drug Targets Diagnostic Imaging of Hepatocellular Carcinoma - A Pictorial Essay
Current Medical Imaging Ebola Virus Altered Innate and Adaptive Immune Response Signalling Pathways: Implications for Novel Therapeutic Approaches
Infectious Disorders - Drug Targets